Valuation: Erasca, Inc.

Market Cap 5.24B 4.69B 4.34B 3.93B 7.35B 499B 7.47B 52.19B 20.65B 261B 19.68B 19.26B 826B P/E 2026 *
-15.1x
P/E 2027 * -22.8x
Enterprise Value 4.39B 3.93B 3.64B 3.29B 6.16B 418B 6.26B 43.75B 17.3B 219B 16.49B 16.14B 692B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
94.04%
Yield 2026 *
-
Yield 2027 * -
1 day+4.17%
1 week+10.06%
Current month+2.25%
1 month+5.19%
3 months-21.56%
6 months-30.25%
Current year+302.96%
1 week 13.44
Extreme 13.44
15.47
1 month 13.1
Extreme 13.1
16.2
Current year 3.36
Extreme 3.36
24.28
1 year 2.1
Extreme 2.105
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.28
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer 66 10/08/2026
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/8/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/6/26 Free

Director

29,888 0.0096%
1/4/26 Exercice

General Counsel

240,000 0.0772%
Change 5-day change 1-year change 3-year change Capi.($)
+4.17%+10.06%+529.83%+597.21% 5.24B
+0.88%-0.34%+40.64%+73.05% 65.28B
-0.26%+6.91%+11.14%+77.36% 54.57B
+0.47%+3.52%+8.22%+100.95% 53.59B
-2.06%+2.90%+24.07%+48.36% 45.03B
-1.79%+0.19%+19.32%+123.62% 42.17B
-1.65%+0.96%+237.56%+823.66% 39.42B
-2.26%-4.14%+15.38%+45.53% 32.71B
-2.44%-10.49%+20.17%-6.18% 24.01B
+12.10%+16.60%+55.14%+46.15% 26.5B
Average +0.72%+3.15%+96.15%+192.97% 38.85B
Weighted average by Cap. +0.12%+2.38%+51.97%+154.31%

Financials

2026 *2027 *
Net sales - -
Net income -322M -288M -266M -241M -451M -30.61B -458M -3.2B -1.27B -16.01B -1.21B -1.18B -50.7B -228M -204M -189M -171M -320M -21.71B -325M -2.27B -899M -11.36B -856M -838M -35.95B
Net Debt -849M -759M -702M -636M -1.19B -80.73B -1.21B -8.45B -3.34B -42.23B -3.18B -3.12B -134B -762M -681M -630M -571M -1.07B -72.47B -1.09B -7.58B -3B -37.91B -2.86B -2.8B -120B
Projected Income Statement - Annual - Erasca, Inc.
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
26/10/26 US$14.99 +4.17% 6,466,122
23/10/26 US$14.39 +2.49% 3,499,957
22/10/26 US$14.04 -3.11% 2,296,073
21/10/26 US$14.49 -0.89% 3,845,038
20/10/26 US$14.62 +7.34% 4,218,224
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Erasca, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
9
Last Close Price
14.99USD
Average target price
24.11USD
Spread / Average Target
+60.85%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Erasca, Inc.
  1. Stock Market
  2. Stocks
  3. ERAS Stock